Pediatric and adolescent HIV viral load coverage and suppression rates in the context of the COVID-19 pandemic in 12 PEPFAR-supported sub-Saharan African countries in 2019 and 2020.


Journal

PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676

Informations de publication

Date de publication:
2024
Historique:
received: 13 02 2024
accepted: 28 06 2024
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 1 8 2024
Statut: epublish

Résumé

The early period of the COVID-19 pandemic limited access to HIV services for children and adolescents living with HIV (C/ALHIV). To determine progress in providing care and treatment services, we describe viral load coverage (VLC) and suppression (VLS) (<1000 copies/ mL) rates during the COVID-19 pandemic in 12 United States President's Emergency Plan for AIDS Relief (PEPFAR)-supported countries. Data for children (0-9 years) and adolescents (10-19 years) on VLC and VLS were analyzed for 12 sub-Saharan African (SSA) countries between 2019 (pre-COVID-19) and 2020 (during COVID-19). We report the number of viral load (VL) tests, and percent change in VLC and VLS for patients on ART. For 12 countries, 181,192 children had a VL test during the pre-COVID-19 period compared with 177,683 December 2020 during COVID-19. VLC decreased from 68.8% to 68.3% overall. However, 9 countries experienced an increase ranging from a 0.7%-point increase for Tanzania and Zimbabwe to a 15.3%-point increase for Nigeria. VLS increased for all countries from 71.2% to 77.7%. For adolescents the number with a VL test increased from 377,342 to 402,792. VLC decreased from 77.4% to 77.1%. However, 7 countries experienced an increase ranging from 1.8% for Mozambique to 13.8% for Cameroon. VLS increased for all countries from 76.8% to 83.8%. This analysis shows variation in HIV VLC across 12 SSA countries. VLS consistently improved across all countries demonstrating resilience of countries during 2020. Countries should continue to improve clinical outcomes from C/ALHIV despite service disruptions that may occur during pandemic response.

Identifiants

pubmed: 39088480
doi: 10.1371/journal.pgph.0003513
pii: PGPH-D-24-00219
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e0003513

Informations de copyright

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Deborah Carpenter (D)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.

Marisa Hast (M)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.

Nicole Buono (N)

United States Agency for International Development, Washington, District of Columbia, United States of America.

Susan Hrapcak (S)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.

Kimi Sato (K)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.

Rosemary Mrina (R)

Walter Reed Army Institute of Research, United States Military HIV Research Program, Silver Spring, Maryland, United States of America.
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.

Mackenzie Hurlston Cox (MH)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.

Patricia Aladi Agaba (PA)

Walter Reed Army Institute of Research, United States Military HIV Research Program, Silver Spring, Maryland, United States of America.
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.

Alexandra C Vrazo (AC)

United States Agency for International Development, Washington, District of Columbia, United States of America.

Hilary Wolf (H)

US Department of State, Office of the United States Global AIDS Coordinator, Washington, District of Columbia, United States of America.

Emilia D Rivadeneira (ED)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.

Judith D Shang (JD)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Yaounde, Cameroon.

Magdalene Mange Mayer (MM)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Yaounde, Cameroon.

Aka Herve Prao (AH)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Abidjan, Côte d'Ivoire.

Henri Onema Longuma (HO)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of Congo.

Constantin Kabwe (C)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of Congo.

Patricia Nyembo Lwana (PN)

Ministry of Health, National AIDS Control Committee, Kinshasa, Democratic Republic of Congo.

Tsegaye Tilahun (T)

United States Agency for International Development, Addis Ababa, Ethiopia.

Mamorapeli Ts'oeu (M)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Maseru, Lesotho.

Immaculate Mutisya (I)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nairobi, Kenya.

Lennah Nyabiage Omoto (LN)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nairobi, Kenya.

Jessica Greenberg Cowan (JG)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Maputo, Mozambique.

Maria Ines Jorge Tomo de Deus (MIJT)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Maputo, Mozambique.

Omodele Johnson Fagbamigbe (OJ)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nigeria.

Uzoma Ene (U)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nigeria.

Akudo Ikpeazu (A)

Federal Ministry of Health, Abuja, Nigeria.

Mduduzi B Ndlovu (MB)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Pretoria, South Africa.

Eva Matiko (E)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Dar es Salaam, Tanzania.

Nicolas Schaad (N)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Dar es Salaam, Tanzania.

Jema Bisimba (J)

United States Agency for International Development, Dar es Salaam, Tanzania.

Elizabeth Lema (E)

United States Agency for International Development, Dar es Salaam, Tanzania.

Kebby Musokotwane (K)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Lusaka, Zambia.

Talent Maphosa (T)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Harare, Zimbabwe.

Buyile Buthelezi (B)

United States Agency for International Development, Pretoria, South Africa.

Adegbenga Olarinoye (A)

HJF Medical Research International, Abuja, Nigeria.

Ismail Lawal (I)

US Army Medical Research Directorate-Africa/ Walter Reed Army Institute of Research, Abuja, Nigeria.

Solomon Mukungunugwa (S)

United States Agency for International Development, Harare, Zimbabwe.

Janet Tulibonywa Mwambona (JT)

Walter Reed Army Institute of Research (WRAIR), Dar es Salaam, Tanzania.

Teferi Wondimu (T)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Addis Ababa, Ethiopia.

Immaculate Anne Kathure (IA)

United States Agency for International Development, Nairobi, Kenya.

Onyeka Donald Igboelina (OD)

United States Agency for International Development, Abuja, Nigeria.

Valery Nxima Nzima (VN)

United States Agency for International Development, Yaounde, Cameroon.

Rosine Grace Bissai (RG)

United States Agency for International Development, Yaounde, Cameroon.

Matjeko Lenka (M)

United States Agency for International Development, Maseru, Lesotho.

Willibrord Shasha (W)

United States Agency for International Development, Abidjan, Côte d'Ivoire.

N'guetta-Kan Olivier (NK)

United States Agency for International Development, Abidjan, Côte d'Ivoire.

Mѐrcia Matsinhe (M)

United States Agency for International Development, Maputo, Mozambique.

Argentina Wate (A)

United States Agency for International Development, Maputo, Mozambique.

Lingenda Godfrey (L)

United States Agency for International Development, Lusaka, Zambia.

Heather Alexander (H)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.

George Alemnji (G)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.

Shirley Lecher (S)

Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.

Classifications MeSH